Cannara Biotech Stock Price, News & Analysis

Cannara Biotech (LOVFF) has achieved significant recognition and financial milestones in June 2025. The company won two prestigious awards at the 6th Annual Grow Up Awards Gala, with its Tribal brand securing Brand of the Year and Nugz Happle winning Accessory of the Year. On the financial front, Cannara has successfully reduced its cost of debt through two key actions: a $1 million partial repayment of the Olymbec convertible debenture and a 50 basis point reduction in the interest rate spread on its BMO Credit Facility, bringing overall debt costs below 6%. The company operates two mega facilities in Quebec totaling over 1,650,000 sq. ft., focusing on premium-grade cannabis production at competitive prices.

Cannara Biotech (LOVFF) reported strong Q2 2025 financial results, with net revenues reaching $26.6 million, a 35% increase from Q2 2024. The company achieved record profitability with gross profit before fair value adjustments rising 52% to $10.8 million and improved gross margins of 41%.

The company delivered its sixteenth consecutive quarter of positive Adjusted EBITDA, more than doubling to $7.1 million. National market share increased to 3.9%, with notable gains in Quebec (12.8%), Ontario (2.9%), and Alberta (2.7%). Net income reached $3.3 million, compared to a loss of $3.4 million in Q2 2024.

Operationally, Cannara is expanding its cultivation capacity with two new grow zones being activated in April and May 2025, bringing total active grow zones to 12 and expanding active canopy to over 300,000 sq. ft., supporting annual production capacity of up to 40,000 kg.

Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF), a vertically integrated premium cannabis producer with two mega facilities in Québec totaling over 1,650,000 sq. ft., has scheduled its fiscal Q2 2025 financial results announcement for April 28, 2025 at 7:00 a.m. ET.

The company will host an earnings webcast on April 29, 2025, at 11:00 a.m. ET, featuring CFO Nicholas Sosiak. The session will include prepared remarks and a Q&A segment. Investors can access the webcast through the company's website and submit questions in advance via email to investors@cannara.ca.

Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) has appointed Justin Cohen as an independent director to its Board and Audit Committee member. Cohen brings extensive experience in brand development, sales, and marketing from his roles at various companies.

As former Chief Marketing and Chief Commercial Officer at Psycho Bunny, Cohen led a tenfold revenue increase over three years through retail expansion and digital acceleration. His experience includes leadership positions at Keurig Dr Pepper, Google, ALDO Group, and Sony Music. Currently, he serves as a senior executive at Cosmetic Physician Partners, overseeing marketing across 55+ U.S. clinics.

The appointment aligns with Cannara's strategy to position its three flagship brands – Tribal, Nugz, and Orchid CBD – as leading cannabis brands in Canada. The company operates two mega facilities in Québec spanning over 1,650,000 sq. ft.

Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) has announced its participation in the Ventum Capital Markets Canadian Cannabis Conference on March 12th, 2025, at 1:40PM-2:00pm EST. The company's CEO Zohar Krivorot and CFO Nicholas Sosiak will deliver a presentation and engage with investors.

As a vertically integrated premium-grade cannabis producer, Cannara operates two mega facilities in Québec covering over 1,650,000 sq. ft. The presentation will highlight the company's:

• Impressive financial performance
• Rapid market share growth
• Cost advantages through Québec operations
• Efficient scaling while maintaining strong margins

The company stands out as one of Canada's fastest-growing and most profitable cannabis producers, maintaining profitability while others in the industry face challenges.

Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) has announced significant financial restructuring through extensions and amendments to its credit facilities. The company has secured an extension of its BMO credit facility to December 31, 2027, which includes a $34.8 million term loan facility, a $10 million revolving credit facility, and a $5.6 million letter of credit.

Additionally, the Olymbec Convertible Debenture, initially worth $5.7 million, has been extended to March 31, 2028, with modified terms including partial repayment rights and a 10.75% interest rate. The company has also engaged Integral Wealth Securities for market-making services at $6,000 monthly and Impaq Capital for investor relations services at $7,500 monthly.

Cannara Biotech (LOVFF) reported record Q1 2025 financial results with net revenues of $25.1 million, up 29% from Q1 2024. The company achieved a Canadian market share of 4.1%, representing a 28% quarter-over-quarter increase.

Key financial highlights include:

• Gross profit before adjustments grew 23% to $9.8 million
• Record Adjusted EBITDA of $6.0 million
• Operating cash flow increased to $5.8 million from $0.8 million in Q1 2024
• Record free cash flow of $4.6 million compared to -$2.0 million in Q1 2024
• Earnings per share increased to $0.03

The company plans to activate two additional grow zones and launch over 20 new products in 2025. Gross profit margins improved to 39% in Q1 2025, up from 30% in Q4 2024, driven by expanded production capacity and higher yields.

Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) announces updates regarding its 2024 Annual General Meeting amid Canada Post strike. The meeting will be held virtually on January 30, 2025, at 11:00 a.m. (Montréal time). Due to the nationwide postal strike that began November 15, 2024, the company will rely on CSA Coordinated Blanket Order 51-913 for exemption from sending physical proxy materials.

The virtual meeting will address standard annual matters including director elections, auditor appointment, and approval of stock option and restricted share unit compensation plans. Shareholders can access meeting materials through SEDAR+ or Cannara's website, and participate via webcast or teleconference. The company operates two mega facilities in Québec spanning over 1,650,000 sq. ft., producing premium-grade cannabis products.

Cannara Biotech (TSXV: LOVE) (OTCQB: LOVFF) has announced an upcoming investor webcast scheduled for Thursday, December 19th, 2024, at 2:00 PM ET. The company, a vertically integrated cannabis producer operating two mega facilities in Quebec with over 1,650,000 sq. ft. of space, will feature CFO Nicholas Sosiak presenting key financial and operational results for the fiscal year ended August 31, 2024.

The presentation will be followed by an interactive Q&A session where investors can engage directly with management. Pre-registration is required through the provided Zoom webinar link, and an archived version of the webcast and presentation will be available on Cannara's investor relations website.